Recce Pharmaceuticals Hits Major Milestone In Phase I/II UTI/Urosepsis Trial

Recce Pharmaceuticals Ltd. is a company that pioneers a novel class of synthetic anti-infectives. The company announced that it has finished dosing another cohort in its Phase I/II UTI/Urosepsis trial, which is assessing RECCE® 327 (R327) administered at rapid infusion rates. It is being said that an Independent Safety Committee will review and assess the complete data from the 6-subject cohort, with preliminary results anticipated in the upcoming weeks. The data collected from this trial is anticipated to set the stage for a Phase II efficacy trial for UTI/Urosepsis, potentially positioning R327 as a leading treatment. Rapid intravenous infusion of antibiotics has been shown to be a safe and effective approach that greatly benefits the treatment process of patients, shortens wait times, and reduces nursing workloads globally.

James Graham, Chief Executive Officer of Recce Pharmaceuticals mentioned "We have successfully reached a new milestone in this trial by administering a 4,000mg dose over a fast 20-minute infusion to all subjects, the highest dosage achieved so far in this trial.” He further added “This is a significant step forward in bringing us closer to establishing R327 as a leading treatment for patients with UTIs or urosepsis."

Upon the completion of the trial, comprehensive data showcasing the efficacy of R327 through intravenous administration will be released in accordance with the study protocol. Further details about this trial can be accessed on the Australia New Zealand Clinical Trial Registry under the trial ID ACTRN12623000448640.